Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced on Oct 17, 2025 that its Compensation Committee granted non-qualified stock options totaling 27,400 shares as inducement awards to newly hired employees, effective Oct 15, 2025.

The awards were made under the companys 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing price on the Grant Date and vest over four years with 25% vesting at the first anniversary and the remainder vesting in equal monthly installments, subject to continued employment.

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 27,400 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on October 15, 2025 (the “Grant Date”), in connection with the commencement of employment.

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
        
Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

What did Aligos (ALGS) announce on October 17, 2025 about inducement grants?

Aligos said its Compensation Committee granted non-qualified stock options for a total of 27,400 shares to newly hired employees, with a Grant Date of Oct 15, 2025.

What is the exercise price for the ALGS inducement options granted Oct 15, 2025?

The exercise price is equal to the closing price of Aligos common stock on the Grant Date (Oct 15, 2025).

How do the ALGS inducement options vest for employees?

The options vest over four years: 25% on the first anniversary of the Grant Date, then the remainder in equal monthly installments, subject to continued employment.

Under what plan were Aligos inducement grants made (ALGS)?

The awards were granted under Aligos 2024 Inducement Plan, used exclusively for individuals not previously employed by the company.

Why did Aligos use an inducement grant under Nasdaq Rule 5635(c)(4)?

Aligos used an inducement grant because the awards were granted to individuals newly hired and were material to their commencing employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Will the ALGS inducement grants dilute existing shareholders and by how much?

The announcement states 27,400 shares were granted; the company did not quantify overall dilution or outstanding share count in the announcement.